Symbols

ANAB

AnaptysBio·NASDAQ

--(--)

ANAB Profile

Anaptysbio, Inc.

A clinical-stage biotechnology company focused on innovative immunology therapeutics

Industry

Biological Technology

Established Date

Listing Date

01/26/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

104

Fiscal Year Ends

12-31

Website

www.anaptysbio.com

Security Type

Common stock

Office address

10770 Wateridge Circle, Suite 210, San Diego, CA 92121

Business

Introduction

AnaptysBio, Inc., established in Delaware in November 2005. The company is a clinical-stage biotechnology company focused on providing innovative immunotherapies for autoimmune and inflammatory diseases. The company's clinical-stage R&D pipeline includes rosnilimab, a selective pathogenic T-cell scavenger, which has completed a Phase IIb clinical trial for the treatment of moderate to severe rheumatoid arthritis (RA). In addition, its R&D pipeline includes ANB033, a CD122 antagonist currently undergoing Phase Ib clinical trials for the treatment of celiac disease (CeD) and eosinophilic esophagitis (EoE); and ANB101, a BDCA 2 modulator currently undergoing Phase Ia clinical trials. AnaptysBio has also discovered a variety of therapeutic antibodies through financial collaborations and licensed them to GSK, including licensing the PD-1 antagonist Jemperli (dostarlimab-gxly) to GSK and the IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals Inc.